urodynam
studi
use
understand
bladder
function
diagnos
bladder
diseas
develop
treatment
dysfunct
ideal
perform
awak
subject
howev
anim
model
especi
cat
common
model
spinal
cord
injuri
associ
bladder
patholog
anesthesia
often
requir
procedur
research
confound
studi
compar
effect
select
agent
dexmedetomidin
alfaxalon
propofol
isofluran
urodynam
bladder
capac
bladder
complianc
nonvoid
contract
bladder
pressur
slope
anesthet
chang
heart
rate
averag
heart
rate
hr
reflex
inductionrecoveri
time
paramet
repeat
cystometrogram
across
five
adult
male
cat
greatest
propofol
bladder
capac
highest
nonvoid
contract
greatest
propofol
dexmedetomidin
highest
bladder
pressur
slope
initi
final
portion
cystometrogram
respect
cat
progress
deeper
plane
anesthesia
lower
hr
smaller
decreas
reflex
dexmedetomidin
compar
propofol
alfaxalon
time
induct
shortest
propofol
time
recoveri
shortest
dexmedetomidin
agentspecif
differ
urodynam
anesthet
paramet
cat
facilit
appropri
studyspecif
anesthet
choic
urodynam
studi
cystometrogram
cmg
use
studi
bladder
function
diagnos
bladder
diseas
even
develop
treatment
bladder
dysfunct
ideal
subject
awak
unanaesthet
studi
howev
anesthesia
confound
urodynam
outcom
often
requir
mani
anim
model
urodynam
studi
particularli
treatment
bladder
dysfunct
test
experiment
paradigm
requir
control
anim
state
cat
common
anim
model
spinal
cord
injuri
associ
bladder
patholog
despit
rel
small
bodi
size
spinal
cord
similar
length
anatomi
human
spinal
cord
urodynam
studi
awak
cat
challeng
placement
indwel
bladder
cathet
awak
studi
invas
lead
complic
cystiti
temporari
cathet
placement
urodynam
trial
necessit
administr
anesthet
agent
interfer
autonom
reflex
vari
degre
agent
minim
inhibitori
toward
autonom
reflex
urethan
recommend
surviv
procedur
due
concern
prolong
recoveri
carcinogen
current
literatur
shown
differ
cmg
paramet
bladder
capac
peak
pressur
nonvoid
contract
nvc
base
differ
anesthet
agent
studi
limit
especi
cat
knowledg
studi
character
follow
agent
use
clinic
veterinari
medicin
cat
cmg
paramet
alfaxalon
dexmedetomidin
propofol
without
use
anoth
anesthet
dexmedetomidin
commonli
use
sedativeanesthet
veterinari
medicin
facilit
cmg
test
laboratori
due
eas
administr
intramuscular
im
rapid
recoveri
revers
agent
atipamezol
howev
rat
studi
dexmedetomidin
inhibitori
volum
evok
micturit
reflex
peak
pressur
compar
urethan
awak
trial
propofol
anesthet
agent
use
facilit
cmg
test
clinic
veterinari
medicin
compar
directli
dexmedetomidin
cat
trial
suspect
less
inhibitori
dexmedetomidin
due
mechan
action
propofol
analges
properti
dexmedetomidin
abil
care
titrat
anesthet
depth
intraven
iv
infus
unfortun
propofol
given
iv
often
requir
anoth
agent
secur
iv
access
alfaxalon
recent
approv
unit
state
use
cat
similar
mechan
action
clinic
applic
propofol
use
cat
context
urodynam
studi
unlik
propofol
alfaxalon
formul
im
dose
requir
addit
agent
studi
anesthet
male
cat
alfaxalon
dexmedetomidin
propofol
lowest
anesthet
dose
practic
facilit
cmg
test
prior
termin
procedur
use
isofluran
assess
effect
anesthet
agent
cmg
anesthet
paramet
hypothes
anesthet
agent
would
inhibitori
toward
bladder
function
other
vascular
access
port
vap
place
prior
trial
ensur
propofol
could
studi
independ
without
need
anoth
agent
five
cat
anesthet
least
time
agent
supplementari
tabl
least
cmg
trial
conduct
per
session
collect
termin
isofluran
trial
four
five
cat
due
one
unexpect
death
bladder
capac
differ
significantli
agent
fig
supplementari
tabl
supplementari
tabl
bladder
capac
greatest
ml
significantli
increas
compar
alfaxalon
ml
p
dexmedetomidin
ml
p
propofol
ml
p
bladder
capac
isofluran
ml
significantli
increas
compar
dexmedetomidin
p
addit
also
differ
significantli
agent
fig
supplementari
tabl
supplementari
tabl
trial
propofol
greatest
cm
significantli
increas
compar
isofluran
cm
p
fig
complianc
differ
significantli
agent
p
pairwis
comparison
supplementari
tabl
supplementari
tabl
nonvoid
contract
rate
highest
nvcss
significantli
higher
agent
p
comparison
fig
supplementari
tabl
supplementaryt
alfaxalon
nvcss
second
highest
rate
nvc
significantli
greater
dexmedetomidin
lowest
rate
nvc
nvcss
p
amplitud
nonvoid
contract
differ
agent
p
trend
cmg
bladder
pressur
respons
chang
agent
differ
agent
variabl
period
passiv
fill
compar
activ
contract
trial
notabl
propofol
cmg
respons
character
earli
gradual
rise
longer
period
activ
contract
compar
dexmedetomidin
respons
character
long
period
low
pressur
passiv
contract
rapid
rise
immedi
void
fig
supplementari
tabl
bladder
pressur
trend
agent
fell
propofol
dexmedetomidin
extrem
describ
quantif
slope
select
time
point
fig
slope
start
second
void
propofol
cm
significantli
increas
compar
alfaxalon
cm
p
dexmedetomidin
cm
p
slope
void
void
highest
slope
cm
significantli
higher
dexmedetomidin
cm
p
alfaxalon
cm
p
slope
void
void
event
dexmedetomidin
cm
significantli
greater
agent
alfaxalon
cm
p
chloralos
cm
p
isofluran
cm
p
propofol
cm
p
mean
hr
mean
vari
agent
fig
fig
supplementari
tabl
supplementari
tabl
mean
hr
compar
across
five
agent
highest
alfaxalon
bmp
significantli
greater
agent
bmp
p
dexmedetomidin
p
isofluran
bmp
p
propofol
bmp
p
agent
fell
two
extrem
mean
chang
heart
rate
compar
across
nontermin
agent
lowest
dexmedetomidin
bmp
significantli
differ
propofol
bmp
p
alfaxalon
bmp
p
mean
differ
significantli
propofol
alfaxalon
p
two
trial
propofol
exclud
averag
continu
hr
plot
fig
fig
gener
reflex
show
greater
anesthet
depth
dexmedetomidin
compar
alfaxalon
propofol
although
jaw
tone
tighter
dexmedetomidin
fig
advers
consequ
associ
vap
placement
includ
surgic
dehisc
port
failur
cat
port
failur
last
propofol
trial
perform
isofluran
induct
order
facilit
iv
cathet
placement
dexmedetomidin
caus
vomit
immedi
inject
session
cat
vomit
agent
cat
vomit
least
dexmedetomidin
one
cat
independ
incid
lethargi
vomit
unassoci
anesthet
event
diagnos
dissemin
lymphoma
necropsi
one
cat
display
signific
bradycardia
nd
degre
atrioventricular
av
block
arrhythmia
dexmedetomidin
separ
anesthet
event
echocardiogram
subsequ
necropsi
cat
suggest
evid
left
ventricular
diastol
dysfunct
myofibril
degener
atrophi
final
alfaxalon
trial
result
unexpect
death
recoveri
cri
discontinu
one
cat
becam
apneic
abl
resuscit
studi
demonstr
differ
urodynam
paramet
anesthet
depth
minim
dose
need
perform
cmg
test
male
cat
knowledg
first
studi
examin
cmg
paramet
alfaxalon
propofol
isol
without
anoth
agent
dexmedetomidin
comparison
agent
use
studi
incorpor
novel
method
cmg
assess
bladder
pressur
slope
conjunct
tradit
cmg
paramet
care
evalu
anesthet
depth
togeth
result
provid
recommend
anesthet
choic
base
studi
paramet
interest
logist
feasibl
cmg
studi
male
cat
due
crossspeci
common
respons
anesthet
agent
select
inform
studi
may
abl
guid
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
preliminari
anesthet
choic
speci
includ
human
howev
feasibl
effect
urodynam
anesthet
paramet
confirm
speci
question
bladder
capac
increas
due
inhibit
central
nervou
system
reflex
anesthesia
postop
urinari
retent
studi
bladder
increas
seen
termin
agent
isofluran
fig
strongli
correl
prolong
anesthesia
isofluran
hour
cmg
trial
hour
total
follow
hour
cmg
trial
repeat
bladder
fill
experiment
object
although
see
signific
differ
surviv
agent
dexmedetomidin
report
caus
polyuria
blockag
argininevasopressin
releas
maximum
detrusor
pressur
pdet
max
also
use
assess
bladder
function
report
account
posit
differ
trial
may
affect
baselin
pressur
consist
previou
studi
examin
pdet
max
found
higher
propofol
lower
isofluran
fig
may
attribut
lighter
plane
anesthesia
propofol
gener
anesthet
depress
pdet
max
dosedepend
manner
human
studi
show
even
compar
anesthet
depth
propofol
show
less
suppress
cortic
somatosensori
evok
potenti
compar
isofluran
altern
increas
may
relat
loss
function
initi
void
reflex
propofol
evidenc
bladder
slope
drastic
differ
awak
state
result
propofol
difficult
interpret
isofluran
avoid
studi
pdet
max
key
paramet
interest
nonvoid
contract
phasic
pressur
increas
seen
bladder
fill
may
link
sensat
relat
bladder
volum
like
frequent
occur
urinari
bladder
patholog
consist
understand
maintain
spinal
reflex
rel
anesthet
agent
greatest
number
nvc
observ
fig
alfaxalon
trial
next
greatest
number
nvc
nontermin
agent
studi
notabl
dexmedetomidin
almost
complet
elimin
nvc
compar
agent
mediat
analges
properti
dexmedetomidin
may
block
sensat
bladder
fill
spinal
supraspin
level
clinic
dexmedetomidin
use
analgesia
prevent
postop
catheterrel
bladder
discomfort
howev
awak
cmg
trial
significantli
less
nvc
anesthet
trial
absenc
nvc
necessarili
patholog
nvc
desir
ex
overact
bladder
model
nonsurviv
alfaxalon
surviv
consid
dexmedetomidin
avoid
studi
cmg
bladder
pressur
slope
differ
agent
fig
interpret
previous
describ
variabl
period
passiv
fill
activ
contract
pressur
slope
dexmedetomidin
character
flat
fill
period
follow
sharp
rise
void
event
similar
awak
anim
cystometrogram
contrast
pressur
slope
propofol
obviou
chang
awak
slope
character
earli
rapid
rise
less
obviou
void
event
although
standard
criteria
defin
passiv
fill
activ
contract
found
propofol
consist
reach
higher
normal
pressur
compar
dexmedetomidin
across
normal
time
obviou
separ
note
normal
time
mean
normal
pressur
standard
deviat
rang
dexmedetomidin
distinctli
separ
correspond
rang
propofol
fig
previou
rat
studi
use
singl
anesthet
agent
tiletaminezolazepam
vari
dose
found
lighter
anesthesia
associ
awakelik
bladder
curv
howev
studi
found
dexmedetomidin
deeper
plane
anesthesia
associ
awakelik
bladder
respons
compar
gabaerg
agonist
lighter
plane
anesthesia
discrep
suggest
suppress
bladder
reflex
may
directli
correl
other
anesthet
depth
anesthet
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
reflex
measur
studi
heart
rate
exact
signific
bladder
pressur
slope
unclear
recommend
investig
bladder
pressur
respons
trend
futur
studi
associ
anesthet
depth
pharmacokinet
preserv
spinal
reflex
well
potenti
bladder
patholog
addit
affect
cmg
urodynam
paramet
agent
offer
uniqu
logist
benefit
constraint
dexmedetomidin
agonist
conveni
administ
im
bolus
cri
recommend
analgesia
sedat
anesthesia
rapidli
revers
atipamazol
provid
conveni
method
anesthet
cat
due
natur
im
bolu
administr
depth
anesthesia
therefor
bladder
function
vari
plasma
level
dexmedetomidin
increas
decreas
common
advers
effect
dexmedetomidin
includ
bradycardia
arrhythmia
av
block
vomit
notic
experi
propofol
alfaxalon
gabaa
agonist
use
clinic
induc
iv
maintain
cri
repeat
iv
bolu
anesthesia
mainten
anesthesia
use
cri
allow
steadyst
drug
plasma
level
stabl
plane
anesthesia
propofol
limit
iv
administr
alfaxalon
given
im
singleag
anesthesia
common
side
effect
propofol
alfaxalon
apnea
although
one
studi
show
alfaxalon
less
respiratori
depress
compar
propofol
unexpectedli
experienc
death
recoveri
phase
common
time
anestheticrel
death
one
alfaxalon
trial
knowledg
isol
incid
repres
gener
safeti
alfaxalon
studi
abl
deceas
concentr
gabaerg
agonist
recommend
label
dose
part
due
stabl
plane
anesthesia
associ
cri
administr
could
one
explan
lighter
plane
anesthesia
preserv
reflex
higher
averag
heart
rate
greater
chang
heart
rate
trial
observ
gabaerg
agonist
compar
dexmedetomidin
fig
howev
anoth
concurr
explan
increas
heart
rate
gabaerg
agonist
hypotens
reflex
tachycardia
contrast
dexmedetomidin
caus
vasoconstrict
lead
hypertens
reflex
bradycardia
consist
previou
studi
dog
show
alfaxalon
caus
less
cardiovascular
depress
propofol
observ
mean
heart
rate
alfaxalon
slightli
upper
limit
awak
refer
rang
significantli
higher
propofol
fig
isofluran
exact
mechan
action
unknown
suspect
affect
gaba
receptor
primari
inhal
anesthet
use
veterinari
medicin
especi
prolong
invas
procedur
although
studi
use
termin
procedur
clinic
veterinari
medicin
isofluran
commonli
use
recoveri
procedur
inhal
rout
administr
allow
dose
easili
titrat
adjust
depth
anesthesia
howev
inhal
agent
logist
challeng
either
requir
technic
expertis
intub
anim
risk
personnel
exposur
sinc
recoveri
isofluran
rapid
isofluran
previous
use
facilit
propofol
administr
urodynam
procedur
effect
isofluran
subsequ
propofol
trial
studi
assum
minim
nonsurviv
hypnot
mechan
unknown
provid
light
longlast
anesthesia
minim
analgesia
minim
effect
normal
spinal
sympathet
reflex
function
unfortun
recommend
surviv
studi
due
involuntari
excit
prolong
recoveri
although
sever
studi
success
recov
anim
follow
anesthesia
limit
studi
includ
follow
lack
direct
comparison
awak
cmg
trial
inabl
full
random
due
logist
constraint
drug
avail
abil
secur
iv
access
etc
although
effort
made
spread
agent
agent
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
test
within
first
trial
within
next
trial
within
final
trial
inabl
extrapol
data
femal
cat
limit
data
termin
agent
isofluran
due
natur
experi
unexpect
death
one
anim
lack
blind
data
analysi
experi
especi
qualit
measur
anesthet
reflex
lack
monitor
data
heart
rate
due
measur
artifact
anim
movement
trial
inabl
control
differ
dose
rout
administr
singl
drug
due
logist
consider
sampl
size
futur
direct
address
limit
includ
addit
rout
dose
singl
agent
concurr
cmg
awak
cat
direct
comparison
anesthet
cat
fill
exvivo
postmortem
bladder
provid
truli
passiv
bladder
control
five
adult
intact
male
domest
shorthair
cat
month
kg
marshal
bioresourc
inc
north
rose
ny
includ
studi
anim
avail
studi
cohort
size
similar
relev
studi
anim
group
hous
temperatur
humid
control
room
hour
lightdark
cycl
ad
libitum
access
water
fed
complet
diet
adult
cat
purina
one
urinari
tract
health
formula
purina
proplan
en
nestl
purina
neenah
wi
cat
free
felin
herpesviru
caliciviru
panleukopenia
coronaviru
felin
immunodefici
viru
chlamydia
toxoplasmosi
experiment
procedur
perform
aaalac
accredit
institut
accord
standard
establish
guid
care
use
laboratori
anim
approv
univers
michigan
institut
anim
care
use
committe
cat
implant
vap
clearport
mid
vap
round
tip
cathet
access
technolog
skoki
il
guarante
immedi
iv
access
iv
access
essenti
avoid
second
agent
propofol
experi
use
provid
constant
rate
infus
cri
alfaxalon
propofol
experi
maintain
anesthesia
cat
induc
dexmedetomidin
mgkg
dexmedse
dechra
overland
park
ks
ketamin
mgkg
zetamin
vet
one
bois
id
butorphanol
mgkg
torbuges
zoeti
kalamazoo
mi
maintain
isofluran
fluriso
vet
one
bois
id
incis
made
left
ventral
neck
dorsal
neck
back
cathet
insert
secur
left
jugular
vein
tunnel
subcutan
port
secur
muscl
shoulder
blade
port
access
noncor
huber
needl
access
technolog
skoki
il
flush
regularli
weekli
use
lock
solut
tc
lock
solut
access
technolog
skoki
il
heparin
salin
cat
anesthet
least
three
time
session
three
agent
dexmedetomidin
mgkg
im
bolu
revers
match
volum
atipamezol
antisedan
orion
corpor
espoo
finland
session
alfaxalon
mgkg
im
bolu
mgkgmin
iv
cri
alfaxan
multidos
jurox
inc
kansa
citi
mo
propofol
mgkg
iv
bolu
mgkgmin
iv
cri
hospira
inc
lake
forest
il
effort
made
random
session
agent
test
within
first
trial
within
next
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
trial
within
final
trial
full
random
could
achiev
due
logist
constraint
agent
avail
repeat
trial
etc
session
differ
day
least
day
previou
anesthet
session
termin
procedur
conjunct
studi
cat
anesthet
dexmedetomidineketaminebutorphanol
combin
vap
surgeri
transit
isofluran
mgkg
induct
mgkg
mainten
everi
hour
need
milliporesigma
burlington
supplement
mgkg
buprenorphin
least
two
cmg
trial
conduct
session
warm
salin
pump
mlmin
infus
pump
baxter
deerfield
il
phd
harvard
apparatu
holliston
fluid
warmer
hotlin
fluid
warmer
smith
medic
minneapoli
mn
one
lumen
duallumen
urethra
cathet
fr
polyurethan
uvc
cathet
utah
medic
midval
ut
urinari
bladder
nontermin
session
steril
prepar
perin
region
cathet
perform
mitig
infect
lumen
cathet
connect
pressur
transduc
pressur
transduc
smith
medic
minneapoli
mn
labchart
adinstru
colorado
spring
co
record
bladder
capac
void
event
occur
urin
would
leak
around
cathet
collect
tray
fig
bladder
empti
break
least
minut
given
trial
allow
bladder
relax
bladder
capac
calcul
maximum
total
volum
infus
sum
urin
collect
bladder
collect
tray
variabl
analyz
cmg
bladder
capac
chang
pressur
baselin
maximum
complianc
number
amplitud
nonvoid
contract
nvc
slope
bladder
pressur
pressur
slope
three
interv
defin
time
later
recumb
initi
agent
inject
time
head
walk
ten
consecut
step
without
fall
record
anesthet
session
nontermin
agent
session
vital
heart
rate
electrocardiogram
puls
oximetri
hemoglobin
satur
puls
oximetri
tongu
lip
ear
noninvas
blood
pressur
forelimb
temperatur
rectal
monitor
everi
minut
use
vital
monitor
surgivet
smith
medic
minneapoli
mn
respiratori
rate
taken
manual
averag
heart
rate
mean
hr
trial
appear
consist
indic
anesthet
plane
later
includ
statist
analysi
vital
either
fluctuat
across
session
subject
artifact
analyz
across
session
procedur
three
five
cat
data
logger
use
continu
vital
record
per
second
calcul
chang
heart
rate
trial
nontermin
studi
reflex
palpebr
withdraw
jaw
tone
pupil
dilat
check
cmg
trial
palpebr
withdraw
reflex
categor
ye
strong
withdraw
weak
withdraw
withdraw
jaw
tone
categor
tight
mid
intermedi
loos
pupil
dilat
categor
constrict
mid
intermedi
dilat
gener
anesthet
depth
increas
palpebr
withdraw
reflex
decreas
jaw
tone
loosen
pupil
becom
dilat
bladder
pressur
data
process
use
matlab
mathwork
natick
excel
microsoft
redmond
wa
bladder
pressur
smooth
use
second
move
averag
nvc
identifi
matlab
use
findpeak
function
defin
peak
least
cm
least
second
away
anoth
peak
manual
confirm
account
rang
trial
length
nvc
count
divid
total
length
trial
calcul
nvc
per
second
quantifi
overal
bladder
pressur
trend
seen
agent
pressur
slope
calcul
three
distinct
time
period
infus
start
second
void
second
void
last
second
void
visual
chang
seen
slope
calcul
differ
pressur
time
rang
across
cat
test
session
bladder
pressur
normal
start
peakvoid
x
time
axi
note
pressur
significantli
fluctuat
rest
baselin
pressur
normal
time
unit
normal
time
unit
rang
target
pressur
normal
within
window
continu
heart
rate
read
nontermin
trial
last
cat
also
process
similarli
entir
length
trial
statist
analyz
use
jmp
pro
sa
institut
inc
cari
nc
use
mix
model
approach
set
anesthet
agent
fix
variabl
anim
random
variabl
analysi
bladder
capac
cat
weight
set
addit
fix
variabl
nomin
categor
data
convert
ordin
categor
data
order
fit
mix
model
yessomeno
tightmidloos
constrictedmiddil
convert
respect
pairwis
comparison
made
use
tukey
hsd
signific
defin
p
relev
data
report
mean
standard
deviat
dataset
gener
analyz
current
studi
matlab
code
use
data
analysi
avail
open
scienc
framework
repositori
http
doi
cat
implant
vap
anesthet
lowest
dose
necessari
facilit
urodynam
test
least
session
propofol
dexmedetomidin
alfaxalon
conduct
addit
termin
experi
isofluran
conjunct
anoth
studi
anesthet
session
least
cmg
trial
perform
session
assess
urodynam
paramet
heart
rate
reflex
use
assess
anesthet
depth
time
inductionrecoveri
note
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
